K
Knut Jørgen Labori
Researcher at Oslo University Hospital
Publications - 105
Citations - 7130
Knut Jørgen Labori is an academic researcher from Oslo University Hospital. The author has contributed to research in topics: Pancreatic cancer & Pancreatectomy. The author has an hindex of 22, co-authored 96 publications receiving 5334 citations. Previous affiliations of Knut Jørgen Labori include University of Oslo.
Papers
More filters
Journal ArticleDOI
Tumour exosome integrins determine organotropic metastasis
Ayuko Hoshino,Bruno Costa-Silva,Tang-Long Shen,Gonçalo Rodrigues,Ayako Hashimoto,Milica Tesic Mark,Henrik Molina,Shinji Kohsaka,Angela Di Giannatale,Sophia Ceder,Swarnima Singh,Caitlin Williams,Nadine Soplop,Kunihiro Uryu,Lindsay A. Pharmer,Tari A. King,Linda Bojmar,Alexander E. Davies,Yonathan Ararso,Tuo Zhang,Haiying Zhang,Jonathan M. Hernandez,Joshua Mitchell Weiss,Vanessa D. Dumont-Cole,Kimberly Kramer,Leonard H. Wexler,Aru Narendran,Gary K. Schwartz,John H. Healey,Per Sandström,Knut Jørgen Labori,Elin H. Kure,Paul M. Grandgenett,Michael A. Hollingsworth,Maria de Sousa,Sukwinder Kaur,Maneesh Jain,Kavita Mallya,Surinder K. Batra,William R. Jarnagin,Mary S. Brady,Øystein Fodstad,Volkmar Müller,Klaus Pantel,Andy J. Minn,Mina J. Bissell,Benjamin A. Garcia,Yibin Kang,Yibin Kang,Vinagolu K. Rajasekhar,Cyrus M. Ghajar,Irina Matei,Héctor Peinado,Jacqueline Bromberg,Jacqueline Bromberg,David Lyden +55 more
TL;DR: It is demonstrated that exosomes from mouse and human lung-, liver- and brain-tropic tumour cells fuse preferentially with resident cells at their predicted destination, namely lung fibroblasts and epithelial cells, liver Kupffer cells and brain endothelial cells.
Journal ArticleDOI
Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver
Bruno Costa-Silva,Nicole M. Aiello,Allyson J. Ocean,Swarnima Singh,Haiying Zhang,Basant Kumar Thakur,Basant Kumar Thakur,Annette Becker,Ayuko Hoshino,Milica Tesic Mark,Henrik Molina,Jenny Xiang,Tuo Zhang,Till Martin Theilen,Guillermo García-Santos,Caitlin Williams,Yonathan Ararso,Yujie Huang,Gonçalo Rodrigues,Tang-Long Shen,Knut Jørgen Labori,Inger Marie Bowitz Lothe,Elin H. Kure,Jonathan M. Hernandez,Alexandre Doussot,Saya H. Ebbesen,Paul M. Grandgenett,Michael A. Hollingsworth,Maneesh Jain,Kavita Mallya,Surinder K. Batra,William R. Jarnagin,Robert E. Schwartz,Irina Matei,Héctor Peinado,Ben Z. Stanger,Jacqueline Bromberg,David Lyden,David Lyden +38 more
TL;DR: It is shown that PDAC-derived exosomes induce liver pre-metastatic niche formation in naive mice and consequently increase liver metastatic burden and suggests that exosomal MIF primes the liver for metastasis and may be a prognostic marker for the development of PDAC liver metastasis.
Journal ArticleDOI
Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Knut Jørgen Labori,Matthew H.G. Katz,Ching W Tzeng,Bjørn Atle Bjørnbeth,Milada Cvancarova,Bjørn Edwin,Elin H. Kure,Tor J. Eide,Svein Dueland,Trond Buanes,Ivar P. Gladhaug +10 more
TL;DR: MMT completion is strongly associated with reduced mortality risk in patients with resectable PDAC undergoing the SF approach and the need for strategies to improve patient selection and reduce surgical morbidity is underscored.
Journal ArticleDOI
Symptom profiles and palliative care in advanced pancreatic cancer—a prospective study
TL;DR: ESAS was useful for assessment of symptom prevalence and intensity and is a clinically adequate method for symptom control and a multidisciplinary approach is necessary for the best palliation of symptoms at the time of diagnosis and during follow-up.
Journal ArticleDOI
Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.
Knut Jørgen Labori,Kristoffer Lassen,Dag Hoem,Jon Erik Grønbech,Jon Arne Søreide,Jon Arne Søreide,Kim Erlend Mortensen,Rune Smaaland,Halfdan Sorbye,Caroline S. Verbeke,Caroline S. Verbeke,Svein Dueland +11 more
TL;DR: The NorPACT–1 trial aims to test the hypothesis that overall mortality at one year after allocation of treatment can be reduced with neoadjuvant chemotherapy in surgically treated patients with resectable pancreatic cancer.